Adicet Bio (ACET)

• Market cap: $59.2M
• 1 day: 3.61%
• 5 days: 6.77%
• 1 month: -2.06%
• 3 months: 5.26%
• 6 months: -18.35%
• Year to date: -24.35%
• 1 year: -51.85%
• 5 years: -95.10%
• 10 years: -99.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

5.16% less ownership

Funds ownership: 67.55% [Q1] → 62.39% (-5.16%) [Q2]

13% less funds holding

Funds holding: 56 [Q1] → 49 (-7) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 15

25% less capital invested

Capital invested by funds: $42M [Q1] → $31.5M (-$10.6M) [Q2]

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 443% upside
• Avg. target: $4 443% upside
• High target: $4 443% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns

443% upside $4

Buy Assumed

23 Jul 2025